問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Digestive System Department

Division of Hematology & Oncology

Division of Infectious Disease

Digestive System Department

Linkou Chang Gung Medical Foundation (在職)

Division of Nephrology

Division of General Internal Medicine

更新時間：2023-09-19

張智翔Chang, Chih-Shiang
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • franwisandsun@gmail.com

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張智翔

List

19Cases

2020-04-01 - 2023-12-31

Phase III

Completed
Open-Label Randomised Controlled Trial of Efepoetin Alfa for Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not on Dialysis (ND-CKD). A Non- Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)

  • Condition/Disease

    Anaemia Associated With Chronic Kidney Disease

  • Test Drug

    Efepoetin alfa

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated6Sites

2024-02-01 - 2028-12-31

Phase III

Active
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure

  • Condition/Disease

    Chronic Kidney Disease and High Blood Pressure

  • Test Drug

    tablet

Participate Sites
11Sites

Recruiting11Sites

2023-11-10 - 2027-12-31

Phase III

Active
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    capsule

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2024-12-01 - 2030-12-31

Phase III

Active
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure

  • Condition/Disease

    Chronic Kidney Disease and High Blood Pressure

  • Test Drug

    tablet

Participate Sites
8Sites

Recruiting8Sites

2025-12-01 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2021-02-25 - 2024-06-05

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-08-31 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Not yet recruiting9Sites

Recruiting9Sites

2024-03-01 - 2026-12-31

Phase I

Active
A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LBL-01 Injection in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injective

Participate Sites
3Sites

Recruiting3Sites

2018-10-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2018-01-01 - 2023-12-18

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB